News | Radiation Therapy | August 19, 2015

UC San Diego study finds majority of reimbursement tied to factors other than patient and/or type of cancer

radiation costs, vary, Medicare cancer patients, UC San Diego, Journal of Oncology Practice

August 19, 2015 — Cost of radiation therapy among Medicare patients varied most widely because of factors unrelated to a patient or that person’s cancer, reported University of California, San Diego School of Medicine researchers. Their findings were published online in the Journal of Oncology Practice.

Year of diagnosis, location of treatment, clinic type and individual radiation provider accounted for 44 to 61 percent of the variation in cost for patients with breast, lung and prostate cancer therapies, according to the study. Factors associated with the patient or patient’s tumor accounted for less than 3 percent of the variation in the cost of radiation therapy.

“We found that variability in Medicare reimbursement for radiotherapy does not depend on individual characteristics of patients or their cancers,” said James Murphy, M.D., assistant professor at UC San Diego School of Medicine and radiation therapist at Moores Cancer Center at UC San Diego Health. “Rather, reimbursement was tied to the provider, geography and technology used to treat patients. This strongly suggests inefficiency within the current Medicare reimbursement framework for radiation therapy.”

Up to two-thirds of patients with cancer receive radiation therapy. Researchers focused on breast, prostate and lung cancers because they represent the most common malignancies treated with radiotherapy.

The cost of radiation therapy was estimated from Medicare reimbursements for outpatient radiation treatment. The total cost of radiation therapy for the 55,288 patients in the study was estimated to be more than $831 million.

“Understanding why costs vary for radiation therapy helps policy makers evaluate the efficiency of the current fee-for-service Medicare reimbursement system. Such insights are likely to shape policy reforms in the near-future,” said Anthony Paravati, M.D., first author of the study.

The authors acknowledge that the study does not consider the relationship between cost of radiotherapy and quality of care, therefore higher cost radiation could lead to higher quality radiation. The link between cost and quality of care represents a future research question the authors hope to answer.

For more information: www.jop.ascopubs.org


Related Content

News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Point-of-Care Ultrasound (POCUS)

Jan. 22, 2026 — Qure.ai has received a grant from the Gates Foundation to develop a large open-source multi-modal ...

Time January 23, 2026
arrow
News | Remanufactured Refurbished Equipment

Jan. 11, 2026 — The Global Refurbished Medical Imaging Equipment Market Size is projected to grow at a CAGR of 15.07% ...

Time January 23, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
Subscribe Now